Please ensure Javascript is enabled for purposes of website accessibility

Is BioNTech More Than a One-Trick Pony?

By Brian Orelli, PhD and Keith Speights - May 9, 2021 at 9:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The German drugmaker has additional drugs in its pipeline beyond its coronavirus vaccine.

BioNTech (BNTX -2.91%) is famous for its coronavirus vaccine, but the biotech has  additional drug candidates in the works. In this video from Motley Fool Live, recorded on April 5, Contributors Brian Orelli and Keith Speights discuss BioNTech's pipeline and what's in store for the company's future.

Brian Orelli: Then as biotechs are apt to do, BioNTech also gave an update during its fourth-quarter results on its pipeline. Any thoughts on what the mRNA specialist is going to do next?

Keith Speights: Yeah. The main thing to watch with BioNTech is still BMT162b2, the COVID-19 vaccine. There's still a lot of work going on with Pfizer (PFE -1.40%) and BioNTech. The two companies are evaluating a third dose to potentially provide additional protection against the South African variant. They're testing the vaccine in kids ages six months to 12 years old. They also have a single-dose lyophilized or freeze-dried version that's in late-stage testing. They expect results from that study in the third quarter. That could be a big story for both of these companies to potentially have a single-dose version of the vaccine. Maybe even more importantly, have a version of the vaccine that doesn't require cold storage. There's some good things that could be on the way for BioNTech just with the COVID-19 vaccine development.

The company is also moving its other pipeline candidates forward. BioNTech said that they expect to advance three oncology programs into phase 2 testing this year. Also, they are advancing six oncology programs from pre-clinical into phase 1 testing. Those are some big stories there. By the way, not all of those are messenger RNA programs. We think of BioNTech in terms of MRNA because of the COVID vaccine. But the company has some other areas of focus as well. They have some non mRNA programs, including a couple of checkpoint immunomodulators that are in early stage testing, they've got a CAR T cell therapy, it's in phase 2 testing. They're not just mRNA, although they're famous for mRNA right now.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$147.61 (-2.91%) $-4.43
Pfizer Inc. Stock Quote
Pfizer Inc.
$48.58 (-1.40%) $0.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.